Collateral for a security interest recorded Jun 26, 2026 (JPMorgan Chase Bank, N.A.).
Term ends Jul 25, 2027 · Medium confidence
20-year base term ends Dec 20, 2026
Why Medium: A parent in the chain could not be resolved.
Held by Soleno Therapeutics, Inc.
Filed Mar 18, 2013 as application 13/846,542 · Granted Jul 5, 2016
Base term plus 217 days of patent term adjustment (USPTO delay)
Today
2006
2027
Clock starts
Dec 20, 2006
Dec 20, 2006
Term ends
Jul 25, 2027
Jul 25, 2027
Granted
Jul 5, 2016
Jul 5, 2016
base term
patent term adjustment
fee events
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
217
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 217 days past its 20-year base term on prosecution delay. 2 of 2 maintenance fees are paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 20, 2006, when application 11/614,044, the earliest non-provisional in its chain, was filed (this one was filed Mar 18, 2013); a parent in its chain could not be resolved (the next row) | Dec 20, 2026 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | +217 days, USPTO patent term adjustment record | Jul 25, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 25, 2027 | Medium confidence |
This family
| US 7,799,777 | In force Mar 2029 | Mar 2029 |
| US 7,572,789 | In force no later than Dec 2026 | no later than Dec 2026 |
| Application 12/819,155 | Abandoned not computed | not computed |
| US 9,381,202 | this patent Jul 2027 | Jul 2027 |
| US 10,085,998 | In force Dec 2026 | Dec 2026 |
| Application 16/110,621 | Abandoned not computed | not computed |
| US 11,045,478 | In force Dec 2026 | Dec 2026 |
| US 11,786,536 | In force Dec 2026 | Dec 2026 |
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 16, 2017 Reel 42470, frame 234 | Cowen, Neil M.; Kashkin, Kenneth B.; Yamout, Khaled A. | Essentialis, Inc. | Assignment of Assignor's Interest |
| Dec 17, 2024 Reel 69613, frame 369 | Soleno Therapeutics, Inc.; Essentialis, Inc. | Oxford Finance LLC, as Collateral Agent | Security Interest |
| Mar 12, 2025 Reel 70494, frame 42 | Soleno Therapeutics, Inc.; Essentialis, Inc. | Oxford Finance LLC, as Collateral Agent | Amended and Restated Intellectual Property Security Agreement |
| Dec 3, 2025 Reel 73832, frame 312 | Essentialis, Inc. | Soleno Therapeutics, Inc. | Assignment of Assignor's Interest |
| May 19, 2026 Reel 75778, frame 94 | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc.; Essentialis, Inc. | Release of Security Interest (REEL 069613, Frame 0369) |
| May 19, 2026 Reel 75601, frame 687 | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc.; Essentialis, Inc. | Release of Security Interest (REEL 070494, Frame 0042) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc. | Release of Security Interest (REEL 070494, Frame 0042) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Essentialis, Inc. | Release of Security Interest (REEL 070494, Frame 0042) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Soleno Therapeutics, Inc. | Release of Security Interest (REEL 069613, Frame 0369) |
| May 19, 2026 reel/frame not recorded | Oxford Finance LLC, as Collateral Agent | Essentialis, Inc. | Release of Security Interest (REEL 069613, Frame 0369) |
| Jun 26, 2026 Reel 75106, frame 487 | Soleno Therapeutics, Inc. | JPMorgan Chase Bank, N.A., as Administrative Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jul 2027
Term ends Jul 25, 2027. No further fees fall due before then
Note
The 217 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
12
later US patents cite this one
That is above the median of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.